NCT05927298 (ProsperPanc) is a clinical trial of Non-interventional in Pancreas Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT05927298?

NCT05927298 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT05927298?

Interventions in NCT05927298: Non-interventional.

What condition does NCT05927298 study?

NCT05927298 studies Pancreas Cancer.

Is NCT05927298 still recruiting?

NCT05927298 is currently active, enrolled. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT05927298: ProsperPanc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial

Active, enrolled Last updated 20 February 2026

What this trial tests

trial testing Non-interventional in Pancreas Cancer in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 March 2023

Primary endpoint
6 March 2027

6 March 2027

Quick facts

Lead sponsor	University Health Network, Toronto
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	200
Start date	6 March 2023
Primary completion	6 March 2027
Estimated completion	6 March 2027
Sites	1 location across Canada

Drugs / interventions tested

Non-interventional

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-centre, translational and observational study. Two cohorts of patients with pancreatic ductal adenocarcinoma (PDAC) are eligible to enroll 1) Upfront resectable PDAC 2) Advanced (unresectable PDAC or metastatic). Patients will have tissue either at resection or from a biopsy at enrolment processed for whole genome sequencing, RNA sequencing and for establishment of patient derived organoids (PDOs). Background epidemiological history and outcome data will be prospectively annotated. Serial blood and stool samples will be collected for exploratory analyses. All electronic medical record information will also be collected. Data will be used to determine if an integrated correlative analysis of whole genome sequencing/RNAsequencing (WGS/RNAseq) and PDOs in the enrolled population will increase the number of patients receiving a precision-matched treatment in Ontario

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
Organoid-based precision medicine in pancreatic cancer.
Beutel AK, Ekizce M, Ettrich TJ, Seufferlein T, et al · · 2025 · cited 9× · PMID 39540683 · DOI 10.1002/ueg2.12701
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.
Wang Y, Zhang L, Wang LZ, Cao Y, et al · · 2025 · cited 4× · PMID 40855314 · DOI 10.1186/s12943-025-02429-0
Multiscale Construction, Evaluation, and Application of Organoids.
Ma W, Dong Z, Zheng Z, Bai L, et al · · 2025 · cited 2× · PMID 41214890 · DOI 10.1002/advs.202508534

Verify or expand the search:

Other trials of Non-interventional

Trials testing the same drug.

NCT06798298 — A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells · recruiting
NCT06746883 — A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacte · recruiting
NCT06622798 — Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients · recruiting
NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
NCT06277037 — Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) · recruiting

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05927298 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05927298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing